Amgen announced it will report its third quarter 2026 financial results on November 3, 2026, after U.S. markets close. The earnings release will be followed by a conference call with CEO Robert A. Bradway and senior management at 4:30 p.m. ET for investors and the public. The call will be webcast live and archived for replay on Amgen's website. This event provides insight into Amgen's financial health and ongoing innovation in biotechnology and medicine development.
Amgen's market cap stands at $242.18 billion as of October 29, 2026, 03:21 WIB, reflecting its significant presence in the health sector. The stock price on Pluang is USD 458.88, up 2.44% in the last day, with a dividend yield of 2.25%. Investor interest remains strong with 82% of Pluang order activity on the buy side, ahead of the company's Q3 earnings webcast scheduled for November 3, 2026.
Amgen announced positive Phase 3 OASIZ-301 trial results for dazodalibep, a CD40L antagonist, showing significant and meaningful reductions in systemic disease activity and patient-reported dryness in adults with moderate-to-severe Sjögren's disease....
Amgen Inc. will announce its Q3 earnings on November 3, following a strong Q2 where non-GAAP EPS rose 25.8% to $6.29, driven by biosimilars and key drugs like Blincyto and Repatha. Recently, Amgen reported encouraging results from a lung cancer drug ...
Amgen has appointed David W. Gibbs, former CEO of Yum! Brands, to its Board of Directors. Gibbs brings extensive leadership experience from the consumer brand sector and will serve on Amgen's Audit and Compensation Committees. His background in digit...
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
